International Practice of Storing Human Cell Lines Intended for Clinical Use

Author:

Rachinskaya O. A.1ORCID,Chaplenko A. A.1ORCID,Melnikova E. V.1ORCID,Semenova I. S.1ORCID,Olefir Yu. V.1ORCID

Affiliation:

1. Scientific Centre for Expert Evaluation of Medicinal Products

Abstract

Currently, the Russian Federation does not have a well-established state-controlled market for cell banks (CB) containing cell material that is potentially applicable for clinical purposes. Cryopreservation of cells in cell bank (CB) is an important step in the production of a number of biomedical cell products and makes it possible to overcome difficulties faced by manufacturers during production and storage of large amounts of cell material. At present there are a large number of human cell lines in the world, which are stored in CB owned by commercial and public organisations in different countries. In addition, new cell lines are being banked every year. All this makes it difficult to find cell material suitable for production purposes or that could potentially be used as donor material in clinics. This study analysed the international practice of storing human cell lines for clinical use. The authors of the study systematised the existing CB worldwide and analysed regulatory documents governing the activities of these banks in different countries. The analysis revealed a trend towards formation of CB, often specialising in certain types of cells, as well as a trend towards creation of registries giving full information about cell lines including data on their scientific application. The increasing development and clinical use of cell therapy products in the Russian Federation and abroad will most likely lead to the increase in the number of CB and registry systems, as well as amounts of materials stored in them, including cell lines intended for clinical use.

Publisher

SCEEMP

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference25 articles.

1. Abbasalizadeh S, Pakzad M, Cabral JMS, Baharvand H. Allogenic cell therapy manufacturing: process development technologies and facility design options. Expert Opin Biol Ther. 2017;17(10):1201–19. http://doi.org/10.1080/14712598.2017.1354982

2. Mel'nikova EV, Merkulova OV, Chaplenko AA, Merkulov VA. Dizain doklinicheskikh issledovanii biomeditsinskikh kletochnykh produktov: osobennosti, klyuchevye printsipy i trebovaniya. BIOpreparaty. Profilaktika, diagnostika, lechenie. 2017;17(3):133–44. [Melnikova EV, Merkulova OV, Chaplenko AA, Merkulov VA. Design of preclinical studies of biomedical cell products: characteristics, key principles and requirements. BIOpreparaty. Profilaktika, diagnostika, lechenie = BIOpreparations. Prevention, Diagnosis, Treatment. 2017;17(3):133–44 (In Russ.)]

3. Harris DT. Stem cell banking for regenerative and personalized medicine. Biomedicines. 2014;2(1):50–79. http://doi.org/10.3390/biomedicines2010050

4. Isasi RM, Knoppers BM. Governing stem cell banks and registries: emerging issues. Stem Cell Res. 2009;3(2–3):96–105. http://doi.org/10.1016/j.scr.2009.05.003

5. Armitage JO. Bone marrow transplantation. N. Engl J Med. 1994;330(12):827–38. http://doi.org/10.1056/NEJM199403243301206

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3